IP Library Granted Patent US 10,280,180
Granted Patent B2
US 10,280,180 · App. 14/408,681 · Granted May 7, 2019

Macrocyclic purines for the treatment of viral infections

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,280,180
App. No.
14/408,681
Granted
May 7, 2019
Kind
B2
Abstract

This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims (17)

1. A compound having formula (I)

or a pharmaceutically accepted salt thereof, wherein

X is oxygen, NH, sulfur or

Y is phenyl or pyridinyl, optionally substituted by one or more substituents independently selected from C 1-6 alkyl, C 1-4 alkoxy, trifluoromethyl or halogen, and

Z is C 1-10 saturated or unsaturated alkyl optionally substituted by an alkyl or alkylhydroxyl; or

Z is C 1-6 alkyl —NH—C(O)—C 1-6 alkyl- or C 1-6 alkyl —NH—C(O—C 1-6 alkyl —O—; or

Z is C 1-10 alkyl —O— wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl; or

Z is C 1-6 alkyl-O—C 1-6 alkyl- wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl; or

Z is C 1-6 alkyl-O—C 1-6 alkyl-O— wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl.

2. A compound selected from the group consisting of:

or a pharmaceutically acceptable salts thereof.

3. A pharmaceutical composition comprising a compound having formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A method of activating TLR7 in a subject comprising administering to the subject a therapeutically effective amount of a compound as claimed in claim 1 .

5. A pharmaceutical composition comprising a compound according to claim 2 and at least one pharmaceutically acceptable excipient, diluent or carrier.

6. A method of activating TLR7 in a subject comprising administering to the subject a therapeutically effective amount of a compound according to claim 2 .

7. A method of inducing interferon in a subject comprising administering to the subject a therapeutically effective amount of a compound of claim 1 .

8. A method of inducing interferon in a subject comprising administering to the subject a therapeutically effective amount of a compound of claim 2 .

Assignments (10)
CHANGE OF NAME Recorded Sep 9, 2020
From: JANSSEN SCIENCES IRELAND UC
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 053740/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: FORTIN, JEROME MICHEL CLAUDE
To: JANSSEN-CILAG FRANCE
Reel/Frame 034595/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: MULLER, PHILIPPE
To: JANSSEN-CILAG FRANCE
Reel/Frame 034595/0592 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: DOUBLET, FREDERIC MARC MAURICE
To: JANSSEN-CILAG FRANCE
Reel/Frame 034595/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: ARNOULT, ERIC PIERRE ALEXANDRE
To: JANSSEN-CILAG FRANCE
Reel/Frame 034595/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: RABOISSON, PIERRE JEAN-MARIE BERNARD
To: JANSSEN INFECTIOUS DISEASES BVBA
Reel/Frame 034595/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: JANSSEN-CILAG FRANCE
To: JANSSEN R&D IRELAND
Reel/Frame 034595/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: JANSSEN INFECTIOUS DISEASES BVBA
To: JANSSEN R&D IRELAND
Reel/Frame 034595/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: BONFANTI, JEAN-FRANCOIS
To: JANSSEN-CILAG FRANCE
Reel/Frame 034595/0480 →